In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Solace Pharmaceuticals Inc.

Latest From Solace Pharmaceuticals Inc.

Creabilis expands senior management team

Earlier in August, Creabilis hired David Roblin from Pfizer as chief medical officer (, 9 August), and now, the company has appointed three more ex-Pfizer employees to its senior management team. Alex Leech joins Creabilis as vice-president and head of finance and operations, and previously served as head of operations at Solace Pharmaceuticals, and head of European project management for the Pfizer R&D organisation. James Sandy was most recently development team leader at Pfizer, and joins Creabilis as senior vice-president and head of development, and Dr Peter Spargo, former head of chemical process R&D for Pfizer, joins as senior vice-president of CMC, the same role he held recently at Novexel.

Novel Pain Therapeutics: When Will Life Get Better On The Island Of Pain?

Nothing has arguably hurt pharmaceutical investors and dealmakers quite so often and with such force as novel pain drug development failures. As a result, a once hot field has gone cold. Despite setbacks, great strides have been made in understanding the complex biology of pain. Scientists have discovered numerous new pain pathway targets with the potential for designing effective agents with fewer off-target effects. Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now understand better how to design drug trials that can segment patient populations to demonstrate therapeutic efficacy more precisely, potentially reducing placebo effects and paving the way for an era of personalized pain medicine.


New CEO at Creabilis

Creabilis (Luxembourg), a clinical-stage biotechnology company creating drugs to treat unmet medical needs in serious dermatological diseases, has named Dr Eliot Forster as its new chief executive officer. Dr Forster has almost 20 years' experience in the biotechnology and pharmaceutical industries. He was most recently CEO of the US-based biotech firm Solace Pharmaceuticals. Before that, he was head of EU development and of development operations in the EU and Asia at Pfizer.

Luxembourg Companies

New Approaches to Neuropathic Pain

In some ways, neuropathic pain seems an odd choice of focus for a small start-up. It comes in many forms and its mechanisms are poorly understood. Moreover, the size and strength of those with stakes in the pain market might be another reason for emerging companies to steer clear. Fortunately, they're not. The unmet need is huge: Only one in two patients actually get some relief from existing drugs, in part because their mechanisms of action are fairly generalized. There remains plenty to be done in identifying and understanding the precise mechanisms behind the various flavors of neuropathic pain. For those whocan figure out new approaches to pain or new uses in pain for failed or overlooked compounds -- the companies profiled in this issue are doing both -- there's a big reward at the end: Sales of neuropathic pain therapies in the seven major pharmaceutical markets reached nearly $5 billion in 2007.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Solace Pharmaceuticals Inc.
  • Senior Management
  • Eric Elenko, PhD, VP, R&D
  • Contact Info
  • Solace Pharmaceuticals Inc.
    Phone: (617) 482-2333
    222 Berkeley Street
    Ste. 1040
    Boston, MA 02116